Semax spray 50mg

Semax Nasal Spray 50mg — The Russian ACTH Nootropic Peptide for Cognitive Enhancement, Mental Focus, BDNF Upregulation, and Neuroprotection

Semax Nasal Spray 50mg delivers one of Russia’s most celebrated and clinically validated nootropic neuropeptides through a precision intranasal metered-dose spray system — the same approved pharmaceutical delivery route used in hospital and clinical settings across Russia and Ukraine. Derived from the adrenocorticotropic hormone (ACTH) fragment 4 to 7 and extended with a stabilising Pro-Gly-Pro sequence to enhance metabolic resistance and bioactivity, Semax is a heptapeptide that has accumulated over three decades of rigorous scientific investigation supporting its capacity to dramatically enhance cognitive performance, upregulate Brain-Derived Neurotrophic Factor (BDNF), protect neurons from ischaemic and oxidative damage, and sharpen focus and mental energy with a pharmacological profile unlike any other compound in the nootropic research landscape. At 50mg per bottle — a high-content format designed for extended research protocols — Semax Nasal Spray 50mg provides researchers with a generous, cost-effective supply of this extraordinary cognitive-enhancing neuropeptide.

What Is Semax Nasal Spray 50mg?

Semax is a synthetic heptapeptide with the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is an analogue of the ACTH fragment 4 to 10, shortened to ACTH (4-7) and extended with a C-terminal Pro-Gly-Pro tripeptide derived from the melanocyte-stimulating hormone release-inhibiting factor (MIF-1). This structural engineering achieves two critical pharmacological goals: it preserves and amplifies the cognitive and neurotrophin-stimulating effects of the ACTH 4 to 7 core sequence while the Pro-Gly-Pro extension confers metabolic stability against rapid enzymatic degradation — substantially extending Semax’s effective duration of action compared to the parent ACTH fragment.

Semax was developed through a collaborative programme between the Institute of Molecular Genetics of the Russian Academy of Sciences and the Engelhardt Institute of Molecular Biology in Moscow, beginning in the 1980s and progressing through decades of preclinical and clinical investigation. It has received regulatory approval in Russia and Ukraine as a pharmaceutical drug prescribed for the treatment of stroke, transient ischaemic attack (TIA), cognitive impairment, optic nerve disease, and peptic ulcer disease — a remarkably broad clinical application portfolio that reflects the depth of its validated therapeutic activity.

The nasal spray format is the approved and standard clinical delivery route for Semax, and the 50mg bottle represents a high-volume research format providing an extended supply at the standard 0.1% clinical concentration — delivering consistent, metered-dose administration across weeks of structured research protocols.

Why Intranasal Delivery Is the Gold Standard for Semax

The Blood-Brain Barrier and Peptide Delivery Challenge

Like all biologically active peptides, Semax faces the fundamental challenge of the blood-brain barrier (BBB) when administered systemically. The BBB’s tight junction endothelium and active efflux transport systems prevent the passage of large, hydrophilic peptide molecules from systemic circulation into the central nervous system in therapeutically meaningful quantities. This means that oral or intravenous administration of Semax would result in negligible brain concentrations — making systemic routes pharmacokinetically inadequate for achieving Semax’s central nootropic and neuroprotective effects. The intranasal route elegantly and completely bypasses this barrier through direct neuronal transport pathways that connect the nasal cavity to the brain.

Olfactory Nerve Transport — Direct Nose-to-Brain Delivery

The olfactory epithelium in the upper nasal cavity is the unique anatomical site where olfactory receptor neurons — the only neurons directly exposed to the external environment — project their axons uninterrupted into the olfactory bulb of the brain. Semax molecules absorbed across the olfactory epithelium are taken up into olfactory receptor neuron axons and transported via axonal flow directly into the olfactory bulb. From there, Semax distributes rapidly into the limbic system, hippocampus, prefrontal cortex, and hypothalamus — the brain regions most relevant to its nootropic, BDNF-stimulating, and neuroprotective mechanisms. This direct olfactory nerve highway from nasal mucosa to brain delivers Semax to its central targets within minutes, completely bypassing the blood-brain barrier.

Trigeminal Pathway and Comprehensive Brain Distribution

Complementing olfactory transport, the trigeminal nerve — which extensively innervates the nasal mucosa — provides a second direct neuronal transport route that delivers Semax to the brainstem, cerebellum, and spinal trigeminal nucleus. The combined olfactory and trigeminal pathways ensure comprehensive brain-wide Semax distribution encompassing both the limbic-cortical targets of its cognitive effects and the brainstem targets of its neuroprotective and anti-ischaemic mechanisms. This is the pharmacokinetic basis for the high central bioavailability that makes the intranasal spray format not merely convenient, but pharmacologically superior to any alternative administration route for central neuropeptide delivery.

Mechanism of Action — How Semax Enhances Cognition and Protects the Brain

Melanocortin Receptor Activation and Dopaminergic Signalling

Semax’s core ACTH (4-7) sequence activates melanocortin receptors — particularly MC4R — in the brain, initiating signalling cascades that increase dopaminergic and serotonergic neurotransmission in the prefrontal cortex, hippocampus, and striatum. Dopaminergic activation in the prefrontal cortex is the neurochemical foundation of Semax’s most immediately noticeable effects: enhanced focus, attention, working memory, mental energy, and executive function. The speed of onset via the intranasal route — with dopaminergic effects detectable within 20 to 30 minutes of administration — makes Semax Nasal Spray one of the fastest-acting cognitive enhancement tools available in the nootropic peptide research field.

BDNF and NGF Upregulation — Neuroplasticity at the Molecular Level

Semax’s most scientifically profound and clinically significant mechanism is its powerful upregulation of Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF) expression in hippocampal, cortical, and basal forebrain neurons. BDNF is the primary molecular driver of synaptic plasticity, long-term potentiation (LTP), neurogenesis in the adult hippocampus, and the formation and consolidation of long-term memories. NGF supports the survival and function of cholinergic neurons in the basal forebrain — the neuronal population most critically responsible for learning, attention, and memory. Published research has demonstrated that Semax produces among the highest BDNF upregulation of any known peptide compound — a 4 to 8-fold increase in hippocampal BDNF mRNA expression in animal models — positioning it as potentially the most potent known peptidergic BDNF stimulator.

Neuroprotection Against Ischaemia and Oxidative Stress

Semax has been extensively studied and approved for clinical use in the treatment and prevention of ischaemic stroke and transient ischaemic attacks. Its neuroprotective mechanisms include reduction of the ischaemic penumbra — the zone of potentially salvageable neurons surrounding an infarct core — through suppression of pro-apoptotic gene expression, reduction of neuroinflammatory cytokine release, enhancement of cerebral blood flow autoregulation, and upregulation of antioxidant enzyme systems. Research in animal stroke models demonstrates that Semax reduces infarct volume, preserves neurological function scores, and accelerates post-stroke cognitive recovery. These clinical applications validate Semax’s neuroprotective mechanisms at the highest level of evidence — approved pharmaceutical use in acute neurological disease.

Key Benefits of Semax Nasal Spray 50mg

1. Rapid-Onset Cognitive Enhancement — Focus, Memory, and Mental Clarity

Semax delivers one of the most pronounced and rapidly apparent cognitive enhancement profiles of any nootropic peptide, with users and research subjects consistently reporting heightened mental focus, sharpened attention, improved working memory, accelerated information processing, and enhanced verbal fluency within 20 to 45 minutes of intranasal administration. These acute cognitive effects are mediated primarily through melanocortin receptor-driven dopaminergic and serotonergic activation in prefrontal circuits. Unlike stimulant-based cognitive enhancers that produce tolerance, overstimulation, and post-dose cognitive crashes, Semax’s receptor-mediated mechanism produces clean, balanced cognitive enhancement without jitteriness, anxiety, cardiovascular stimulation, or rebound fatigue.

2. The Most Potent Peptidergic BDNF Stimulator Known

Among all known peptide compounds, Semax produces the most powerful documented upregulation of BDNF expression. The magnitude of hippocampal BDNF increase achieved by Semax — up to 8-fold in animal

studies — is without parallel among neuropeptides and surpasses the BDNF-stimulating effects of exercise, antidepressants, and most pharmacological agents studied in the context of neuroplasticity research. This extraordinary BDNF-stimulating capacity translates into enhanced memory consolidation, improved learning efficiency, greater synaptic plasticity, accelerated recovery from brain injury, and long-lasting neuroplastic changes that persist beyond the peptide’s pharmacokinetic half-life. For researchers studying BDNF biology, neuroplasticity, and cognitive enhancement, Semax is the definitive reference compound.

3. Approved Neuroprotective Agent for Stroke and Brain Injury

Semax’s regulatory approval in Russia for the treatment of ischaemic stroke and transient ischaemic attacks is one of the most compelling validations of a nootropic peptide’s clinical efficacy in existence. In acute neurological settings, Semax has been shown to reduce neurological deficit severity, decrease mortality and disability rates, and improve long-term functional recovery outcomes in stroke patients when administered within the first hours of ischaemic event onset. For researchers studying neuroprotection, cerebral ischaemia, traumatic brain injury, and neurological recovery, Semax’s approved clinical neuroprotective status provides a level of translational evidence that most research peptides cannot offer.

4. Enhancement of Learning, Memory Consolidation, and Academic Performance

Through its combined BDNF upregulation, LTP enhancement, dopaminergic prefrontal activation, and cholinergic support via NGF stimulation, Semax produces a comprehensive enhancement of both working memory and long-term memory consolidation. Research subjects administered Semax before learning tasks demonstrate superior recall performance, faster acquisition of new information, and improved retention over delay periods compared to controls. The peptide’s ability to enhance both the acute neural substrate for attention and learning and the molecular machinery for memory consolidation makes it uniquely effective across the full learning-to-retention spectrum.

5. Mood Enhancement and Resilience to Mental Fatigue

Through serotonergic modulation in limbic and prefrontal circuits, Semax produces mood-brightening effects that complement and contextualise its cognitive enhancement properties. Research subjects report improved motivation, reduced mental fatigue during sustained cognitive tasks, greater emotional resilience under workload pressure, and enhanced sense of mental wellbeing. These mood effects are qualitatively different from the anxiolytic mood stabilisation of Selank — Semax is more energising and cognitively activating, while Selank is more calming and anxiety-reducing — and the two peptides are frequently researched together for their complementary mood and cognitive profiles.

6. Optic Nerve Protection and Visual System Research

Among Semax’s approved clinical applications in Russia is the treatment of optic nerve disease — a remarkable indication that reflects the peptide’s documented neuroprotective effects in the visual system. Research has demonstrated that Semax protects retinal ganglion cells and optic nerve axons from ischaemic damage, reduces oxidative stress in retinal tissue, and supports the survival and function of photoreceptors and supporting cells in models of visual system injury. This ophthalmological application adds a unique dimension to Semax’s research profile and is of significant interest to researchers studying retinal neuroprotection, glaucoma pathophysiology, and optic nerve regeneration.

Semax vs Selank — Complementary Russian Neuropeptides Explained

Semax and Selank are the two flagship Russian nootropic neuropeptides, frequently discussed together and often researched in combination. Understanding their distinct profiles helps clarify when each is appropriate and why combining them is a popular research strategy:

• Primary Effect — Semax: Cognitive stimulation, focus, energy, BDNF upregulation, neuroprotection. Selank: Anxiety reduction, stress resilience, emotional stability, cognitive clarity through anxiety reduction
• Mechanism — Semax: Melanocortin receptor activation, dopaminergic/serotonergic stimulation, BDNF/NGF upregulation. Selank: GABAergic modulation, enkephalinase inhibition, serotonin metabolism enhancement, tuftsin-derived immunomodulation
• Subjective Profile — Semax: Energising, stimulating, cognitively activating, mentally sharpening. Selank: Calming, anxiolytic, emotionally stabilising, subtly mood-brightening
• Research Applications — Semax: Stroke, cognitive impairment, neuroprotection, BDNF research, optic nerve disease. Selank: Anxiety disorders, stress physiology, immune-brain axis, GAD, asthenia
• Combination Rationale: Semax provides the cognitive activation and neuroprotective BDNF boost; Selank provides the anxiolytic balance and emotional stability — together they produce a calm, highly functional cognitive state that neither peptide achieves alone
• Approved Clinical Uses — Semax: Stroke, TIA, cognitive impairment, optic nerve disease. Selank: Generalised anxiety disorder, asthenic conditions, phobic neuroses

Research Dosage and Administration Protocol

Semax Nasal Spray 50mg is formulated at the standard approved clinical concentration of 0.1% (1mg/ml). The following protocol is based on approved Russian clinical guidelines and published research data:

• Standard Research Dose: 200–600mcg per administration (2–6 actuations of a 100mcg/actuation metered pump)
• Approved Clinical Protocol: 200–400mcg per nostril, 2–3 times daily for acute applications; 200mcg once or twice daily for cognitive enhancement protocols
• Cycle Length: 10–14 days per course, with 1–2 week rest periods between cycles; longer cycles of 4–6 weeks used in clinical settings for stroke rehabilitation
• Onset of Effects: Acute cognitive enhancement apparent within 20–45 minutes; BDNF-mediated neuroplastic effects accumulate over days to weeks of consistent administration
• Timing: Morning administration preferred for cognitive enhancement protocols to align with natural dopaminergic circadian rhythms; pre-task dosing 30–45 minutes before cognitively demanding activities

• Storage: Refrigerate at 2–8°C; protect from light; do not freeze; use within 30 days of opening
• 50mg Bottle Duration: At 400mcg daily (standard research dose), the 50mg bottle provides approximately 125 daily doses — sufficient for multiple complete research cycles

Product Specifications

• Peptide Name: Semax (ACTH 4-7 Pro-Gly-Pro analogue)
• Amino Acid Sequence: Met-Glu-His-Phe-Pro-Gly-Pro
• CAS Number: 80714-61-0
• Molecular Formula: C₃₇H₅₁N₁₁O₁₀S
• Molecular Weight: 813.96 g/mol
• Total Peptide Content: 50mg per bottle
• Concentration: 0.1% w/v (1mg/ml) — standard approved clinical concentration
• Volume: 5ml per bottle
• Delivery Device: Metered-dose nasal spray pump
• Purity: ≥98% (HPLC and mass spectrometry verified)
• Appearance: Clear, colourless to pale-yellow sterile solution
• Storage: 2–8°C; protect from light; do not freeze
• Intended Use: Research and laboratory purposes only

Why Choose Our Semax Nasal Spray 50mg?

Our Semax Nasal Spray 50mg is formulated using pharmaceutical-grade Semax peptide at 98% purity or above, verified by independent third-party HPLC and mass spectrometry analysis confirming the correct Met-Glu-His-Phe-Pro-Gly-Pro sequence. The aqueous formulation is prepared in a sterile, isotonic nasal spray matrix at the standard clinical 0.1% concentration, with pH adjustment for nasal mucosal biocompatibility. The metered-dose delivery device is calibrated for consistent per-actuation volume throughout the bottle’s full content — ensuring that each dose in your research protocol delivers the same concentration and volume of active Semax peptide from the first spray to the last.

Our Quality and Manufacturing Standards

• ≥98% Semax peptide purity verified by independent third-party HPLC chromatography
• Correct heptapeptide sequence (Met-Glu-His-Phe-Pro-Gly-Pro) confirmed by mass spectrometry
• Standard 0.1% clinical concentration in sterile isotonic pH-balanced nasal solution
• Consistent metered-dose pump with verified per-actuation volume uniformity throughout full bottle use
• Sterility-tested final formulation with tamper-evident sealed packaging and full batch traceability
• Certificate of Analysis available on request for every production batch
• Cold-chain shipping in temperature-protective insulated packaging for solution integrity in transit

• Discreet, professional worldwide delivery with responsive expert customer support

Frequently Asked Questions About Semax Nasal Spray 50mg

How quickly does Semax produce cognitive enhancement effects?

Semax Nasal Spray produces its acute dopaminergic cognitive enhancement effects with notably rapid onset via the intranasal route. Most research subjects report noticeable improvements in focus, mental sharpness, and cognitive energy within 20 to 45 minutes of nasal spray administration — one of the fastest onset profiles among all nootropic peptides. These acute effects typically last 4 to 8 hours depending on dose and individual response. The BDNF-mediated neuroplastic effects of Semax are progressive rather than immediate, accumulating over days and weeks of consistent administration as hippocampal and cortical BDNF levels build — meaning that regular Semax administration produces both immediate acute cognitive sharpening and cumulative long-term neuroplastic improvements simultaneously.

What is the advantage of the 50mg bottle over smaller formats?

The 50mg bottle format offers significant advantages for extended research protocols. At the standard approved clinical concentration of 0.1% (1mg/ml), the 50mg bottle contains 5ml of solution — sufficient for approximately 50 full bilateral doses at the 1mg (1,000mcg) per administration dose level, or 125 doses at the standard research dose of 400mcg daily. This extended supply is particularly valuable for longitudinal research designs studying BDNF accumulation, neuroplastic changes, and long-term cognitive or neuroprotective effects that require sustained multi-week administration. The 50mg format also provides the most cost-efficient per-dose value of all available Semax nasal spray formats.

Can Semax and Selank nasal sprays be used in the same research protocol?

Yes. Co-administration of Semax and Selank is one of the most widely studied and discussed combination protocols in Russian neuropeptide research. The two peptides operate through entirely distinct and non-competing mechanisms — Semax via melanocortin receptor activation and BDNF/NGF upregulation, Selank via GABAergic modulation and enkephalinase inhibition — meaning they do not interfere with each other’s pharmacology. In combined protocols, Semax provides the cognitive activation, focus, and neuroplasticity benefits, while Selank provides anxiolytic balance and emotional stability, together producing a comprehensive nootropic effect characterised by calm, high-functioning mental clarity that neither peptide achieves in isolation.